Results 161 to 170 of about 3,341,855 (333)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Single-photon advantage in quantum cryptography beyond QKD. [PDF]

open access: yesNat Commun
Vajner DA   +10 more
europepmc   +1 more source

More on the Science Commons open data protocol

open access: yes, 2008
Thinh Nguyen, Freedom to Research: Keeping Scientific Data Open, Accessible, and Interoperable, <em> Science Commons </em> , April 23, 2008.  (Thanks to the Science Commons blog.)  Nguyen is the Counsel for Science Commons.
openaire   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Protocol, mainstreaming Open Science

open access: yes
Protocol for baselining and bestpractice assessment of Mainstreaming Open Science ...
openaire   +1 more source

Citizen Science Protocol for beach plastic monitoring using aerial drones

open access: green
Mounir Grari   +4 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy